Aarti Pharmalabs Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 5 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹6.2K Cr

CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).

From Aarti Pharmalabs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹817

Market Cap

₹6.2K Cr

P/E Ratio

35.0

How does Aarti Pharmalabs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Aarti Pharmalabs Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr.

Full financials →

📊 Revenue & Sales Performance

→CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth.
→New molecules moving from development to commercial phase will drive sales, with larger growth anticipated in FY '27 and beyond.
→API business to normalize and ramp up in H2 FY '26 after inventory corrections and product mix optimization, including oncology and steroid APIs, with major launches in FY '27 and FY '28.
→Atali plant will become fully operational in 2-3 quarters, boosting Intermediate and CDMO business revenue from FY '27 onward.
→Xanthine capacity expansion to 9,000 tons/year by end of FY '26, with gradual ramp-up over 2-3 years expected to capture ~25% market share.
→Long-term target of INR 1,000 crore revenue from CDMO side in 2-3 years considered achievable.
→Overall EBITDA growth guidance is 8%-12% for FY '26, with a longer-term goal of 15%-20% EBITDA growth over 3 years.

📈 Profitability & Margins

→FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).
→Long-term target remains 15%-20% EBITDA growth over the next 2-3 years, subject to new product launches and market conditions (Page 14).
→CDMO segment expected to exceed earlier 30%-40% growth guidance this year, with substantial sales growth in H2 (Page 14).
→Ganesh Polychem losses expected to reduce, with profitability stabilizing near FY '25 levels by FY '27 (Page 20).
→API segment growth challenging in short-term due to inventory correction but expected to rebound with new oncology launches in FY '27 and FY '28 (Page 11).
→Atali plant to become fully operational by FY '27 contributing meaningfully to revenue (Page 5).
→Overall, management expects recovery and reasonable profit growth from FY '27 onwards after a rough FY '26 (Page 25).

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.
→Xanthine expansion: Capacity increased from 5,000 to 9,000 metric tons (annual installed capacity) by end of FY '26; expansion is brownfield with phased operationalization.
→Facility upgrades: Focus on debottlenecking and standardizing production, including at Ganesh Polychem to improve cost efficiency and profitability.
→Site shifting plan: Future plan to shift Dombivli site within the year as part of strategic operational improvements.
→Ongoing R&D and capacity capitalization: Some projects still under capital work-in-progress (WIP), with more capitalization expected towards year-end.
→Expansion supports future growth, especially in Intermediate and CDMO-CMO business segments.

💰 Fundraising & Capital Structure

→The transcript does not mention any current or future plans for fundraising through debt or equity.
→There is no discussion of new debt issuance or equity offerings during the Q2 FY26 earnings call.
→The company focuses on operational updates, capacity expansions (Atali plant, Xanthine expansion), and growth guidance.
→Financial discipline and long-term customer relationships are emphasized as pillars of progress, suggesting a preference for organic growth.
→No statements indicate plans to raise capital via market instruments in the near future.

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The CDMO-CMO segment currently has 59 active projects, with 39 in the commercial stage and 20 under various stages of development at the customer's end.
→The company is working with 21 customers in this segment and is on track to achieve and exceed the earlier estimated sales target of 30% to 40% Y-o-Y growth.
→Management is actively participating in several RFPs (Requests for Proposals) to increase the CDMO project funnel, including expanding geographical presence in Europe and North America to boost business development.
→New product commercializations and approvals over recent quarters have led to enhanced visibility and long-term potential order book growth.
→Expansion and capacity debottlenecking, particularly in the Xanthine segment and Atali facility, indicate readiness to fulfill growing orders, with full operational capacity expected in 2-3 quarters for Atali and Xanthine capacity expected to ramp up to 9,000 MT by year-end.

Key Metrics

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Pharmalabs Ltd

See full Pharmaceuticals & Biotechnology sector rankings

What AARTIPHARM's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

ALIVUS (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
SOLARA (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
SUNPHARMA (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
ZYDUSLIFE (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q2 FY26 results?

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.